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Purpose: To extend the study of the camel milk proteins which have antiviral activity against HCV, camel naïve
polyclonal IgGs, α-lactalbumin were purified from camel milk and their anti-HCV effect was examined using PBMCs
and Huh7.5 cell-lines. They were compared with the activity of human polyclonal IgGs and camel lactoferrin and
casein.
Material and methods: Three types of experiments were performed on PBMCs and HuH7.5 cell. HCV was directly
incubated with the purified proteins and then mixed with both cell types, or the proteins were incubated with the
cells and then exposed to HCV, or the HCV pre-infected cells were treated with the proteins to inhibit intracellular
replication. The proteins were added to cells or virus at different concentrations and time intervals.
Results: Pretreated PBMCs and Huh7.5 cells with milk proteins were not protected when exposed to HCV infection.
The direct interaction between HCV and camel IgGs and camel lactoferrin (cLf) led to a complete inhibition of HCV
entry into cells, while casein, α-lactalbumin and human IgGs failed to inhibit HCV entry at any tested concentration.
Camel IgGs showed ability to recognize HCV peptides with a significant titer (12 × 103) in comparison with human
IgGs which failed to do it. Camel lactoferrin was capable of inhibiting the intracellular HCV replication at
concentrations of 0.25-1.25 mg/ml.
Conclusion: Camel milk naïve polyclonal IgGs isolated from camel milk could inhibit the HCV infectivity and
demonstrated strong signal against its synthetic peptides. Lactoferrin inhibit the HCV infectivity started from
0.25 mg/ml. However, α-lactalbumin, human IgGs and casein failed to demonstrate any activity against HCV
infectivity.
Keywords: Camel milk proteins, Hepatitis C virus, Screening, InfectivityBackground
Hepatitis C is a global health problem and represents a
major cause of liver disease and a socioeconomic burden
[1], without the existence of any protective vaccine or
effective drug. The potential treatment of the recognized
effective drugs (interferon plus ribavirin and/or pegy-
lated interferon) for hepatitis C virus (HCV) lead to an
impressive sustained virological response that did not
exceed 56 % [1].* Correspondence: redwan1961@yahoo.com
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distribution, and reproduction in any mediumCamel milk is often used as an adjuvant treatment for
several chronic diseases, such as diabetes mellitus, or in
allergic patients [2–7]. However, scientific basis for the
positive effect of camel milk improving the health status
of those patients (especially those suffering from hepa-
titis has to be better understood. Camel milk possesses a
protein system constituted by two major classes of pro-
teins: caseins and whey proteins. Caseins account for
80 % (w/w) of the total milk protein content [8] and
whey contains numerous proteins such as immuno-
globulins, α-lactalbumin, lactoperoxidase, lysozyme and
lactoferrin, among other proteins with biological func-
tions [9]. Lactoferrin plays an important and multifunc-
tional role in innate and specific host defense against
infection by microorganisms, alone or with other milkentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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13]. Lactoperoxidase is present in the milk of many spe-
cies and catalyzes the oxidation of some organic and
inorganic substrates by hydrogen peroxide, such as thio-
cyanate in milk, producing derivate compounds with
antibacterial activity [14]. Lysozyme is another antibac-
terial protein present in milk, tears, saliva, and other
secretions of mammals. The antibacterial activity of lyso-
zyme is exerted by damaging the cell wall of some bac-
teria. It has been shown a great activity of camel milk
lysozyme against Salmonella typhimurium compared to
other types of lysozyme [9].
Camels have a unique and special class of antibodies
which were referred to as Heavy-chain antibodies
(HCAbs) because they lack the classical light-chain and
are composed of a homodimer of heavy-chains [15].
α-lactalbumin is a low molecular weight acidic protein
(14.2 KDa) present in the whey fraction of milk. Re-
cently, the capacity of defending the newborn from
pathogenic microorganisms has been putatively ascribed
to α-lactalbumin [16–18]. α-lactalbumin itself does not
possess any antimicrobial activity; however, when it
changes to a particular conformation it acquires anti-
microbial and antitumoral properties [16]. The aim of
this work was to study: the camel naive polyclonal IgGs
and α-lactalbumin inhibitory activity against HCV, com-
pare their inhibitory activity with human polyclonal
IgGs, confirm and compare with the previously pub-
lished results of camel milk proteins (lactoferrin, casein)
activity on HCV entry and replication in PBMCs and
Huh7.5 cells, inaddition to their positive control roll.
Results
Antibody reactivity against HCV peptides
The HCV peptides were designed to be mostly con-
served within the core and envelope of HCV genotypes.
The tested human polyclonal IgGs presented values of
reactivity against HCV-synthesized peptides similar to
that of the control, though camel antibodies gave posi-
tive results as is shown in Figure 1. Camel naïve poly-
clonal IgGs significantly recognized all the types of HCV
peptides with an affinity up to 25 × 103. Both core pep-
tide 2 and envelope 2 peptide 6 released stronger signal
than the rest of peptides. However, human polyclonal
IVIGs showed very low reactivity with any of the HCV
synthesized peptides (Figure 1).
Cytotoxic effect of camel IgGs, α-lactalbumin, Lf, casein,
or IVIGs
We tested the cytotoxic effects of camel IgGs, α-lactalbu-
min, cLf, casein and IVIGs on PBMCs and Huh7.5 cells
to exclude the possibility of HCV elimination caused by
reduced cell viability. We also wanted to investigate the
in vitro side effects of those proteins on the two types ofcells (normal and hepatoma cells). Cell viability deter-
mined by MTT method was compared with the un-
treated PBMCs and Huh7.5 cells and the results are
shown in Table 1. Our results indicated that camel or
human proteins tested at 1.0 or 2.0 mg/ml did not have
any effect on the viability of the PBMCs or any cytotoxic
effect after 4 days of incubation period, as it presented
values above 89 %. Similar results were obtained when
using Huh7.5 cells, unless for the incubation with camel
casein that reduced cell viability to 10 % and 5 % at pro-
tein concentrations of 1.0 and 2.0 mg/ml, respectively.
Neutralization and protection effects of camel IgGs,
α-lactalbumin, cLf, casein and human IVIGs
Camel IgGs and lactoferrin at concentrations of 0.5 and
1.0 mg/ml were able to completely inhibit or prevent the
entry of HCV particles into PBMCs and Huh7.5 cells as
shown in Figure 2. However, camel α-lactalbumin and all
types of IVIGs at concentrations of 0.5 and 1.0 mg/ml
failed to neutralize HCV particles and prevent these par-
ticles from entry into PBMCs and Huh7.5 as shown in
Figures 2 and 3. The purified camel casein could not be
able either to block the HCV entry to PBMCs at concen-
trations of 0.5 and 1.0 mg/ml, as shown in Figure 3,
though we did not detect HCV band at 174 bp in agarose
gel for both concentrations of casein in Huh7.5 cells.
Our results indicated that all proteins used in the assays
failed to protect human PBMCs and Huh7.5 cells or
block the cell receptors from HCV entry (Figure 3). It
was observed that the HCV band at 174 bp was not
detected in agarose gel when camel casein was added to
Huh7.5 cells as it was also shown in Figure 2, which may
be due to the elimination of HCV caused by a reduced
viability of Huh7.5 cells as described above.
Effect of camel IgGs, Lf, casein, α-lactalbumin and human
IVIGs on replication of HCV
Camel lactoferrin, casein, IgGs, α-lactalbumin and IVIGs
at concentrations of 0.25, 0.5, 0.75, 1.0 and 1.25 mg/ml
were tested for their in vitro ability to inhibit or prevent
HCV particles replication inside the infected PBMC and
Huh7.5 cells. Camel lactoferrin could inhibit HCV repli-
cation only at concentrations from 0.75 to 1.25 mg/ml
after 96 h and at concentrations from 0.25 mg/ml after a
second dose of treatment (another 4 days) as shown in
Figure 4. However, camel IgGs, α-lactalbumin, casein
and IVIGs failed to prevent HCV replication at any con-
centration used (0.25-1.25 mg/ml) after 4 days of treat-
ment as shown in Figure 4. However, HCV band at
174 bp was not detected when we treated HCV infected
Huh7.5 cells with camel casein at any concentration
(Figure 4), that elimination of HCV was caused again by
a reduced viability of Huh7.5 cells, as it has been
described above.
Figure 1 Reactivity of camel IgGs and human IVIG-1, IVIG-2 and IVIG-3 against HCV synthetic peptides 1–6 (A-F), in serial dilutions.
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Table 1 Cell viability of Huh7.5 (A) and PBMC (B)








Concentration 1.0 mg/ml 2.0 mg/ml 1.0 mg/ml 2.0 mg/ml
Control 100 100 100 100
cLf 90 86 100 100
Camel casein 10 5 100 99
Camel IgGs 86 85 100 100
Camel
α-lactalbumin
87 84 100 100
IVIG-1 87 85 100 98
IVIG-2 86 84 100 99
IVIG-3 87 85 100 100
The values are expressed as percentage of control cell viability.
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Nowadays, many research lines are directed to study
some components derived from natural sources, which
might simply improve our life by protecting us and im-
proving our health. Historically, camel’s milk has been
used for medical purposes and treatment of someFigure 2 Activity of cLf (A), camel IgGs (B) and camel
α-lactalbumin (C) against HCV on Huh7.5 cells. In A, B and C,
lanes 1, 2, 3 are DNA ladder, negative and positive control,
respectively; in D, lanes 1, 2, 3 are DNA ladder, positive and negative
control, respectively. Lanes 4 and 5 are cLf, IgGs or α-lactalbumin
through direct interaction with HCV at concentrations of 0.5 and
1.0 mg/ml, respectively. The activity of camel casein at a
concentration of 1.0 mg/ml (D) against HCV through direct
interaction on PBMCs and Huh7.5 is shown in lanes 4 and 5.diseases. Many useful properties are assigned to camel’s
milk that has been traditionally used for the treatment
of tuberculosis, gastroenteritis and allergy, and is also
drunk as a tonic. The beneficial properties of camel’s
milk, among them its antimicrobial activity, can be
attributed to substances such as proteins, lipids, carbo-
hydrates and vitamins. Among milk proteins, lactoferrin,
IgGs, α-lactalbumin, casein, lactoperoxidase, lysozyme,
and some peptides are the main components that have
been suggested to possess those activities [19–22].
In this work, we studied the antiviral activity of camel
IgGs, α-lactalbumin, lactoferrin, and casein in compari-
son with three human commercial intravenous immuno-
globulins G, against hepatitis C virus by determining its
infectivity in Huh 7.5 and PBMCs cell lines. The results
showed that camel IgGs and lactoferrin prevented HCV
from entry into PBMCs and Huh7.5 cells when assessed
by two in vitro assays. The second was an assay based
on the direct interaction of proteins with the virus parti-
cles, and the first one evaluated the protection of the
cells by the proteins. We observed that camel α-lactalbu-
min, casein and human IVIGs at concentrations of 0.5
and 1.0 mg/ml failed to inhibit HCV molecules from
entry into PBMCs and Huh7.5 cells, as shown by both
types of assays. However, the results obtained by electro-
phoretic analysis showed no band corresponding to
HCV when the activity of camel casein was evaluated on
Huh7.5 cells, though that was caused by a reducedFigure 3 Activity of human IVIGs against HCV entry into
Huh7.5, tested through direct interaction between viral
particles and proteins. All panels contain DNA ladder (lane 1),
negative control (lane 2) and amplified 174 bp of HCV in positive
control (lane 3). (A) Lanes 4–9 show the direct interaction between
HCV and IVIG-1, IVIG-2, and IVIG-3 at concentrations 0.5 and
1.0 mg/ml, respectively. (B). Lanes 4–9 represent cLf, IgGs,
lactalbumin, human IVIG-1, IVIG-2 IVIG-3 at concentrations of
1.0 mg/ml, respectively. (C) Activity of camel casein against HCV
entry into PBMCs and Huh7.5 cells. Infected PBMCs incubated with
casein at concentrations of 0.5 and 1.0 mg/ml (lanes 4 and 5) and
Huh7.5 cells incubated with casein at concentrations of 0.5 and
1.0 mg/ml (lanes 6 and 7).
Figure 4 Intracellular inhibition activities of camel IgG (A) and α-lactalbumin (B) on HCV replication in Huh7.5 cell line. DNA ladder
(lane 1), negative control (lane 2), positive control (lane 3) and lanes 4–8 show the effect of IgGs and α-lactalbumin at different concentrations
(0.25, 0.5, 0.75, 1.0 and 1.25 mg/ml) on HCV-infected Huh7.5 cells after four days of treatment. (C) Lanes 4–8 show the effect of first dose of cLf at
various concentrations (0.25, 0.5, 0.75, 1.0 and 1.25 mg/ml) on HCV-infected Huh7.5 cells after first dose of treatment. (D) Lanes 4–5 show the
effect of cLf (0.25 and 0.5 mg/ml) on HCV-infected Huh7.5 after 8 days.
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tosis. The viability of Huh7.5 cells was greatly reduced
and consequently, the HCV amplified 174 bp band could
not be detected, which confirm the previous report [23].
The apoptosis caused by camel casein is in accordance
with the results published in the study of Håkansson
et al. [24] in which it was reported that human casein
(α-lactalbumin bound to casein was implicated in its
apoptotic activity) and bovine α-lactalbumin unfolded
and forming a complex with oleic acid called “human α-
lactalbumin made lethal to tumor cells” (HAMLET),
induced differential and significant apoptosis in several
cancer lines [25,26].
We also described in a previous study [23] that camel
casein at the concentrations used in the present work,
initiated apoptosis in HepG2 cells, reducing their viabil-
ity and consequently, the detection of HCV RNA. No
antiviral activity against different virus has been either
shown by intact bovine casein [27], however, these
authors reported that bovine casein when was chem-
ically modified could acquire antiviral activities [27].
The results of anti-HCV activity of cLf were in agree-
ment with a previous study [28,29] which used cLf toinhibit HCV (genotype 4) entry into human PBMCs and
with another study [30] which showed that cLf inhibited
HCV entry into HepG2 cells. This antiviral activity of
cLf against HCV also agree with previous studies in
other cell lines that reported that human and bovine
lactoferrin inhibited HCV (genotype1) entry into the
non-neoplasic human hepatocyte cell line PH5CH8 [31]
at a concentration limit of 2 mg/ml. Our results showed
that cLf at concentrations of 0.5, 1.0 and 1.25 mg/ml
inhibited HCV replication inside infected cells after the
first dose of treatment (four days) and at concentrations
of 0.25 and 0.5 mg/ml after the second dose of treatment
(another four days).
The inhibitory activity of purified camel polyclonal
IgGs against HCV found in the present work is in agree-
ment with results reported of Martin et al. [32] who
described the inhibitory activity of recombinant camel
VH domain antibody biopanned against HCV NS3 pro-
tease and partially ascribed by a recent study [33].
Camel’s IgG are not limited to one major subclass IgG1,
but includes three main subclasses (IgG1, IgG2 and
IgG3) [32]. IgG2 and IgG3 subclasses are devoid of light
chains and have heavy chains of 45 and 42 kDa,
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tional domain (the N-terminal variable region of the
heavy chain antibodies referred as VH that is the min-
imal intact antigen-binding fragment that can be gener-
ated) of the heavy-chain antibodies interfere with several
biological processes and might make good candidates for
human therapy [34]. IgG2 and IgG3 act as true competi-
tive inhibitors by penetrating into active sites of some
enzymes [32,33]. They might have inhibitory activity on
human immunodeficiency viruses type 1 (HIV-1) reverse
transcriptase, protease, and integrase enzymes that are
crucial to the HIV-1 life cycle [34].
The potential activity of IVIG preparations was used in
the treatment and prophylaxis of infectious diseases and
toxin, and they were also used as specific antibodies against
causative bacterial LPS [35], but at least from the informa-
tion we have available there is no previous study using
human IVIGs in the neutralization of hepatitis C virus
in vitro. We found that cLf acts as a strong anti-HCV agent
and camel IgG acts as an intermediate agent, while camel
casein, α-lactalbumin and IVIGs failed to inhibit HCV.
Camel casein was not able to prevent or neutralize HCV
from cell-entry at both levels, by direct or indirect interac-
tions. Passive immunization with antibodies for the preven-
tion and treatment of diseases become part of medical
therapy, intravenous immunoglobulin being most import-
ant plasma natural product available for therapeutic use
[36–38]. One gram of intravenous immunoglobulin G
(IVIG) contains 4×1018 molecules with more than 107
antibody specificity. This fact leads to a tremendous in-
crease in IVIG availability and its subsequent use in the
clinical setting.
Several evidences demonstrate that neutralizing anti-
bodies are present in patients with chronic hepatitis C,
and the epitopes located within the E2 protein are im-
portant for HCV neutralization. Thus the experimental
preparation made from anti-HCV-positive plasma (HCI-
GIV) prevented HCV infection when mixed with a virus
inoculum ex vivo before infusion into chimpanzees. Un-
fortunately, the in vivo efficacy of HCIGIV in both chim-
panzees and humans has been disappointing [39].
However, the human blood and/or plasma fractions in-
dustry exclude any blood or plasma fraction containing
HCV antibodies [39]. This might explain the historical
evidence that normal immunoglobulins manufactured
before the screening of blood or plasma donor for HCV
infection protected against hepatitis C [35,38].
Conclusion
The importance of camel milk and its components are
increasing day after day. This milk is used as a main
source of nutrients in several arid and non-arid areas
worldwide. Camel IgGs inhibited HCV infectivity as well
as differentially recognized the envelope and coresynthesised HCV peptides. Meanwhile, lactoferrin was
able to block the HCV cell-entry and aborted its intracel-
lular multiplication. Although these results are promis-
ing, more extensive works are on the run to explore the
relationship between lactoferrin structure and its anti-
HCV activity. In addition, deeper studies will be needed




Camel polyclonal IgGs, α-lactalbumin, lactoferrin and
casein were purified from milk of 35 healthy camels as
previously described [18,40]. Human polyclonal intra-
venous immunoglobulins (IVIG) were purchased from
three companies (γ-Globulin-Korean Green Cross Co-
operation (IVIG-1, KGCC), 135–989 Seoul, Korea;
IVIG-2 of Octapharma, 1100 Viena, Austria; IVIG-3 of
VIGAM-S BPL, Herts WD6 3BX, UK), which contain
the natural ratio of IgG1, IgG2, IgG3, IgG4 without IgM
or IgA (the full description of these products are avail-
able in their companies web or in reference [35].
Cell culture and media
Huh7.5 cells were kindly donnated by Prof. Charles
Rice at the Rockefeller University (New York, NY
10065–7919, USA). The culture media, cell preserva-
tion and running of the cultured cells were used as
previously published [41,42]. Peripheral blood cells
(PBMCs) were isolated, as reported by El-Fakharany
et al. [43].
Protein and endotoxin determination
Protein content was determined by directly measuring
the absorbance at 280 nm and by the Bradford method
using bovine serum albumin as standard protein [44].
The endotoxin content was checked to avoid its pyro-
genic effects on the cell-culture system [45]. All purified
proteins used were free of endotoxin (data not shown).
HCV peptides design and synthesis
Harnessing the CLUSTALW multiple sequence align-
ments (http://www. workbench.sdsc.edu) the following
sequences were extracted from Los Almos HCV
sequences database http://hcv.lanl.gov. The six peptide
sequences were extracted from the most conserved
regions and were synthesized commercially (ANASPEC
Inc., San Jose, CA 95131–1314, USA) in the following
design:
Peptide-1 from the HCV core protein
(DVKFPGGGQIVGGVYLLPRR)
Peptide-2 from the HCV core protein
(GPRLGVRATRKTSERSQPRG)
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(IPKARRPEGRTWAQPGY)
Peptide-4 from the HCV core protein
(IPKDRRSTGKSWGKPGY)
Peptide-5 from the HCV envelope1 protein
(QHRMAWDMM)
Peptide-6 from the HCV envelope2 protein
(NLQLINTNGS)
The peptides were synthesized in the amide form
using the standard solid phase synthesis involving 9-
flurenylmethoxy carbonyl chemistry [46] and purified by
HPLC according to the producer construction.
Infected serum samples
For all infection experiments, we utilized PCR-HCV
positive serum samples of genotype 4a from an Egyptian
patients (after approval by ethical committee of the
Genetic Engineering and Biotechnology Research Insti-
tute) as described previously [47]. A clear consent was
obtained from each patient to publish the harvested data.
Immunoassay for determination of camel and human
IgGs reactivity against HCV peptides
ELISA plate was coated with 50 μl of HCV peptides or
BSA as negative control at a concentration of 5 μg/ml,
incubated for 24 h at room temperature then blocked
with 100 μl of blocking buffer (2 % BSA or gelatin in
PBS) for 1 h at room temperature. Then, 50 μl of poly-
clonal camel IgG (3 μg/ml) and IVIG (3 μg/ml) diluted
in 2 % BSA or gelatin-PBS, were added in serial double-
fold dilution. After 1 h of incubation at room
temperature, 50 μl of diluted 1:100 mouse anti-camel
IgGs and mouse anti-human IgGs [48] were added to
wells containing polyclonal camel IgG and IVIG, re-
spectively, incubated for one hour at room temperature
and then 50 μl of alkaline phosphatase–conjugated anti-
mouse IgG (BIO-RAD, Hercules, CA 94547, USA)
diluted 1:2000 with 2 % BSA or gelatin–PBS were added.
Finally, p-Nitrophenyl phosphate (p-NPP) was added for
color development and absorbance recorded at 405 nm
immediately.
Cytotoxic effect of camel IgGs, α-lactalbumin, cLf, casein
and intravenous immunoglobulin G (IVIGs)
Cytotoxicity effect of purified camel IgGs, α-lactalbumin,
cLf, casein, or IVIGs on human separated PBMCs and
Huh7.5 cells was tested by Thiazolyl Blue Tetrazolium
Bromide (MTT) assay [49–51] PBMCs cells and Huh7.5
cells (104) were cultured in 96-well microtiter plates in
duplicate and cultured overnight at 37 °C, then the medium
was refreshed with DMEM supplemented medium con-
taining 1.0 or 2.0 mg/ml of IgGs, α-lactalbumin, cLf, casein,
or IVIGs. Cells treated with proteins were incubated for4 days at 37 °C, 5 % CO2 and 88 % humidity. Afterwards,
20 μl of MTT solution (5 mg MTT/ ml PBS) were added
to each well. The plate was shaken at 150 rpm for 5 min,
to thoroughly mix the MTT into the media. Then, it was
incubated at 37 °C, 5 % CO2 and 88 % humidity for
5 hours to allow the MTT to be metabolized. Finally,
200 μl of dimethylsulfoxide were added to each well,
placed on the shaking table at 150 rpm for 5 min and the
optical density was read at 595 nm [49–51].
Inhibition potential of camel IgGs, α-lactalbumin, cLf,
casein, and IVIGs on HCV
Firstly, the interaction of IgGs, α-lactalbumin, cLf, ca-
sein, or IVIGs with HCV particles was examined by add-
ing 1 ml of 2 % HCV infected serum (6.4 × 106 copies/
mL, genotype 4a) with IgGs, α-lactalbumin, cLf, casein,
or IVIGs for 1 h at 4 °C (final concentrations of 0.5 and
1.0 mg/ml for each protein), then the mixture of HCV
and protein was added to PBMCs leukocytes or Huh7.5
cells cultured as described above, and incubated for
90 min at 37 °C. The cells were washed three times with
PBS and cultured for 7 days at suitable conditions, fol-
lowed by washing three times with PBS and total RNA
was extracted from cells. Secondly, the interaction of
camel IgGs, α-lactalbumin, cLf, casein, or IVIGs with
the human PBMCs and Huh7.5 cells (105), was exam-
ined by adding these proteins at the final concentration
of 1.0 mg/ml to the cells (in DMEM supplemented
medium) and incubated for 1 h at 37 °C. All proteins
were removed by washing the cells three times with
PBS. After addition of 1 ml of medium containing 2 %
infected serum (6.4 × 106 copies/mL, genotype 4a) to
each well, the cells were incubated for 90 min at 37 °C.
The cells were washed three times with PBS and cul-
tured for seven days at 37 °C, followed by total RNA
extraction.
HCV replication inhibition potential of camel Lf, casein,
IgGs, α-lactalbumin and human IVIGs
Human PBMCs and Huh7.5 cells were washed twice in
DMEM media. The PBMCs and Huh7.5 cells were sus-
pended at 1.0 × 105 cells/ml in DMEM culture media.
The cells were left to adhere on the 24-well plates over-
night at 37 °C, then infected with HCV-infected serum
(6.4 × 106 copies) in DMEM media and incubated for
two days at 37 °C. Camel Lf, casein, IgGs, α-lactalbumin
or IVIGs were added at concentrations of 0.25, 0.5, 0.75,
1.0 and 1.25 mg/ml to infected cells. Positive (infected
cells with HCV) and negative control (healthy cells) cul-
tures were included. After four days of incubation at
37 °C, total RNA was extracted from cultured cells. Sec-
ond dose of cLf at concentrations of 0.25 and 0.5 mg/ml
were added to the cells and incubated for another four
days at 37 °C, followed by total RNA extraction.
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PCR of HCV RNA
Extraction of RNA from PBMCs and Huh7.5 cells was
performed as previously described in detail [29]. The re-
verse transcription-nested PCR was carried out by using
plus and minus strand primers [30,43], with some modi-
fication, since the amplification process included a Rulc
plasmid as internal control. The final DNA amplicon
was subjected to 3 % agarose gel electrophoresis and
ethidium bromide was used to visualize 174 bp for HCV
and 374 bp of Rulc.
Statistical analysis
Most measurements were repeated three times and the
results are presented as the mean plus standard devi-
ation. Data were analysed by using Student’s t-test.
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